How Does Dulaglutide Work? Mechanism of Action, Per the Research

Dulaglutide in One Paragraph

Dulaglutide is a prescription, long-acting glucagon-like peptide-1 (GLP-1) receptor agonist given by subcutaneous injection, approved in the United States and Europe for the treatment of type 2 diabetes in adults. Published descriptions of the molecule characterise it as GLP-1 analogue peptides covalently linked to a modified human immunoglobulin Fc fragment, a design intended to resist enzymatic degradation and slow renal clearance so that a single weekly injection maintains receptor exposure. Its pharmacology has been studied in large randomised trials: in the REWIND cardiovascular outcomes trial, researchers assigned adults with type 2 diabetes to dulaglutide 1.5 mg once weekly or placebo and followed them for a median of 5.4 years (PMID 31189511), and in a paediatric trial, dulaglutide 0.75 mg or 1.5 mg once weekly was compared with placebo over 26 weeks in youths aged 10 to under 18 years with type 2 diabetes (PMID 35658022). This page is for educational purposes only and is not medical advice; consult a licensed physician about any medicine, including whether a GLP-1 receptor agonist is appropriate for a particular person.

The Receptor Target: GLP-1R

The primary molecular target described in the pharmacology literature is the GLP-1 receptor (GLP-1R), a class B G-protein-coupled receptor. Native GLP-1 is an incretin hormone released from intestinal L-cells after eating; it has a very short circulating half-life because dipeptidyl peptidase-4 (DPP-4) cleaves it rapidly. Dulaglutide is engineered so that this cleavage site is altered and the molecule is too large for rapid renal filtration, which is the structural basis for once-weekly administration rather than a separate mechanism of action.

GLP-1 receptors are expressed on pancreatic islet beta cells and, at lower density, in the gastrointestinal tract, heart, kidney, vasculature and several brain regions including the hypothalamus and brainstem. The breadth of this expression pattern is why a single receptor target can produce effects on insulin secretion, gastric motility and appetite at the same time. Importantly, dulaglutide is described as selective for GLP-1R; it is not a dual or triple incretin agonist. Receptor-level work on the related dual agonist tirzepatide illustrates how incretin receptor pharmacology is characterised in vitro, that in-vitro and early clinical report described agonist activity at both the GIP and GLP-1 receptors and the cAMP-based assays used to quantify it (PMID 30473097). Dulaglutide, by contrast, engages only the GLP-1 arm of that system.

Signalling downstream of the receptor

Classical pharmacology describes GLP-1R activation as coupling mainly to the stimulatory G protein Gs, which activates adenylate cyclase and raises intracellular cyclic AMP (cAMP). Two cAMP effectors are usually described in beta cells:

• Protein kinase A (PKA), which phosphorylates ion channels and proteins involved in insulin granule handling.
• Epac2 (cAMP-GEF-II), which contributes to the mobilisation of insulin granules toward the plasma membrane.

The combined effect described in the literature is amplification of glucose-stimulated insulin secretion. A frequently emphasised feature of this pathway is glucose dependence: the signalling cascade potentiates insulin release when glucose is elevated and contributes comparatively little when glucose is low, which is the pharmacological explanation given for the low intrinsic hypoglycaemia risk of GLP-1 receptor agonists when used without insulin or sulfonylureas. Clinical physiology work in type 2 diabetes has measured these parameters directly; in a study that included dulaglutide as an active comparator, researchers reported improvements in indices of beta-cell function and insulin sensitivity relative to placebo (PMID 33236115).

Downstream Physiology: What the Receptor Activation Produces

1. Glucose-dependent insulin secretion

The best-characterised consequence of GLP-1R agonism is potentiation of insulin secretion from beta cells in the presence of elevated glucose. Clinical measurements of beta-cell function and insulin sensitivity in people with type 2 diabetes have been used to quantify this effect in trials that included dulaglutide as a comparator arm (PMID 33236115).

2. Suppression of inappropriate glucagon secretion

GLP-1R signalling is described as restraining alpha-cell glucagon release when glucose is normal or high, which reduces hepatic glucose output. This is usually framed as a complementary arm of glycaemic effect alongside insulin secretion, and it, too, is described as glucose-sensitive rather than absolute.

3. Slowed gastric emptying

GLP-1R activation in the gut and brainstem slows the rate at which stomach contents enter the small intestine, blunting post-meal glucose excursions. The same pathway is the mechanistic explanation most often offered for the gastrointestinal adverse events observed across the class, which were among the most frequently reported events in head-to-head trials of once-weekly GLP-1 receptor agonists (PMID 29397376).

4. Central appetite and satiety signalling

GLP-1 receptors in the hypothalamus and brainstem are described as participating in satiety signalling, and reductions in energy intake are the mechanism generally proposed for body-weight changes seen with the class. Weight outcomes have been reported in randomised comparisons; in a head-to-head trial, researchers compared once-weekly semaglutide with once-weekly dulaglutide (semaglutide 0.5 mg versus dulaglutide 0.75 mg, and semaglutide 1.0 mg versus dulaglutide 1.5 mg) and reported differences in glycated haemoglobin and body weight between agents (PMID 29397376). Interest in central GLP-1 signalling has extended to eating behaviour more broadly, although a systematic review of GLP-1 receptor agonists in binge eating described the available evidence as limited and preliminary (PMID 38449772).

Established Mechanism Versus Proposed Mechanism

Not every effect attributed to dulaglutide has an equally well-mapped pathway. The table below separates mechanisms that are directly supported by receptor pharmacology and human physiology measurements from those that remain hypotheses generated by outcome data.

Cardiovascular Findings and Why the Mechanism Is Still Debated

REWIND was a double-blind, randomised, placebo-controlled trial in adults with type 2 diabetes in which dulaglutide 1.5 mg once weekly was compared with placebo over a median follow-up of 5.4 years, and the investigators reported a lower rate of major adverse cardiovascular events in the dulaglutide group (PMID 31189511). The study did not isolate a single causal pathway. Candidate explanations discussed in the broader literature include glycaemic improvement, body-weight and blood-pressure change, lipid and metabolite shifts, and direct GLP-1 receptor effects in vascular and cardiac tissue, none of which that trial was designed to disentangle.

Because of its established cardiovascular dataset, dulaglutide has been used as an active comparator in subsequent outcome research. SURPASS-CVOT was designed as a head-to-head comparison of tirzepatide and dulaglutide for major adverse cardiovascular events in participants with type 2 diabetes and atherosclerotic cardiovascular disease, and its published design paper described the baseline characteristics of that population (PMID 37758044); results from that comparison were subsequently reported (PMID 41406444). Using dulaglutide as the control arm rather than placebo reflects its position as a reference GLP-1 receptor agonist in this field.

How Dulaglutide's Mechanism Differs From Related Molecules

Distinguishing single-receptor from multi-receptor agonists clarifies what dulaglutide does and does not do:

• Other GLP-1 receptor agonists. Same receptor, different molecules and potencies. A randomised open-label trial directly compared once-weekly semaglutide with once-weekly dulaglutide in type 2 diabetes and reported outcomes for glycated haemoglobin, body weight and adverse events (PMID 29397376).
• Dual GIP/GLP-1 receptor agonists. Tirzepatide engages the GIP receptor in addition to GLP-1R; a phase 3 monotherapy trial in Japanese patients with type 2 diabetes compared tirzepatide 5 mg, 10 mg and 15 mg once weekly with dulaglutide 0.75 mg once weekly (PMID 35914543), and a biomarker analysis reported changes in lipid and metabolite profiles in participants receiving tirzepatide or dulaglutide (PMID 34608929).
• Triple agonists. Retatrutide adds glucagon receptor agonism; a phase 2 substudy reported effects on body composition in people with type 2 diabetes (PMID 40609566). Dulaglutide has no glucagon-receptor agonist component.
• Oral small-molecule GLP-1 receptor agonists. Orforglipron is a non-peptide agonist of the same receptor; a phase 2 dose-response study reported efficacy and safety outcomes in type 2 diabetes (PMID 37369232). The receptor is shared, the molecular format is not.

Adverse Events in Dulaglutide Research: What Studies Report

Mechanism and tolerability overlap, because the same gastrointestinal signalling that slows gastric emptying is linked to the most commonly reported side effects. In the randomised head-to-head comparison of once-weekly semaglutide and dulaglutide, researchers reported that gastrointestinal events were the most common adverse events in both treatment groups (PMID 29397376). In the trial of youths aged 10 to under 18 years, the study reported that gastrointestinal adverse events occurred more frequently with dulaglutide than with placebo (PMID 35658022). Safety outcomes were also reported in the phase 3 monotherapy trial that used dulaglutide 0.75 mg once weekly as the comparator arm (PMID 35914543). Prescribing information for GLP-1 receptor agonists carries additional warnings that are evaluated by regulators and by prescribing clinicians, not by this page.

What the Mechanism Does Not Explain

1. Individual response. Receptor pharmacology describes an average pathway, not how any one person will respond; trial averages (PMID 29397376) are population-level results.
2. Durability. Mechanistic descriptions say nothing about how effects persist over years; only long-term trials address that, such as the 5.4-year median follow-up in REWIND (PMID 31189511).
3. Causal attribution for outcomes. Cardiovascular findings were reported as event rates, and the pathway responsible remains a proposed rather than demonstrated mechanism (PMID 31189511, PMID 41406444).
4. Populations not studied. Trial populations were defined by protocol; results in one group cannot be assumed to transfer to another.

Dulaglutide is a prescription medicine. Questions about whether it is suitable for a given person, how it interacts with other medicines, and what monitoring is appropriate belong with a licensed prescribing clinician. This page summarises published pharmacology and trial reports and does not provide dosing or treatment guidance.

References

• Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial (Lancet, 2019)
• Once-Weekly Dulaglutide for the Treatment of Youths with Type 2 Diabetes (New England Journal of Medicine, 2022)
• Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial (Lancet Diabetes & Endocrinology, 2018)
• Dual GIP and GLP-1 Receptor Agonist Tirzepatide Improves Beta-cell Function and Insulin Sensitivity in Type 2 Diabetes (Journal of Clinical Endocrinology and Metabolism, 2021)
• LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept (Molecular Metabolism, 2018)
• Effects of Tirzepatide, a Dual GIP and GLP-1 RA, on Lipid and Metabolite Profiles in Subjects With Type 2 Diabetes (Journal of Clinical Endocrinology and Metabolism, 2022)
• Efficacy and safety of tirzepatide monotherapy compared with dulaglutide in Japanese patients with type 2 diabetes (SURPASS J-mono) (Lancet Diabetes & Endocrinology, 2022)
• Comparison of tirzepatide and dulaglutide on major adverse cardiovascular events in participants with type 2 diabetes and atherosclerotic cardiovascular disease: SURPASS-CVOT design and baseline characteristics (American Heart Journal, 2024)
• Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes (New England Journal of Medicine, 2025)
• Effects of retatrutide on body composition in people with type 2 diabetes: a substudy of a phase 2, double-blind, parallel-group, placebo-controlled, randomised trial (Lancet Diabetes & Endocrinology, 2025)
• Efficacy and safety of oral orforglipron in patients with type 2 diabetes: a multicentre, randomised, dose-response, phase 2 study (Lancet, 2023)
• GLP-1 receptor agonists: A novel pharmacotherapy for binge eating (Binge eating disorder and bulimia nervosa)? A systematic review (Journal of Clinical & Translational Endocrinology, 2024)